Biopharmaceutical company Oncothyreon Inc. has announced that they have enrolled their first patient for a Phase I trial of their oncology product ONT-10, a therapeutic cancer vaccine directed at MUC1. The trial will evaluate issues of safety and immunogenicity in patients with MUC1-expressed cancers, such as cancers of the breast, lungs, ovaries, colon, prostate, pancreas and more.
"We are excited to begin this trial of our proprietary therapeutic vaccine candidate ONT-10," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "We hope that this trial will demonstrate in cancer patients that ONT-10 can stimulate both antibodies and immune cells directed at MUC1, as it has in animal models."
This Phase 1 trial of ONT-10 consists of two parts: The first will consider a dose escalation schedule in up to 48 patients to determine the maximally tolerated / recommended dose of ONT-10 administered either once every other week or once every week over an 8 week period. The second will consider the safety of ONT-10 at the maximally tolerated or recommended dose in up to 15 additional patients at the weekly and/or biweekly schedule.
Both parts of the study will consider the ability of ONT-10 to induce both a humoral and a cellular immune response.
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
